A Retrospective Budget Impact Analysis of Fidaxomicin Treatment for Clostridioides difficile Infections (CDI) in Germany.
Ann-Cathrine SiefenMelina Sophie KurteAnna Marie BauerOliver Andreas CornelySebastian M Wingen-HeimannFlorian KronPublished in: Expert review of pharmacoeconomics & outcomes research (2024)
The analysis indicates FDX treatment can lead to cost savings compared to VAN. Future research should focus on specific patient groups, such as refractory CDI patients.